Stephen A. Barat
Senior Vice President of TherapeuticsDr. Stephen A. Barat, Ph.D is Senior Vice President of Therapeutics of HTG Molecular Diagnostics, Inc. from October 2021. He served with the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen). Prior to joining HTG, Dr. Barat was the U.S. Head, Non-clinical Safety Leaders in Non-clinical Safety Assessment at Janssen, where he led a large team that supported programs in all phases of discovery and development, from target assessment and lead optimization through candidate selection, early/late-stage development and registration. Before Janssen, he served as Vice President, Preclinical Research and Early Development at Scynexis and held additional senior roles at Allergan (Actavis/Forest Laboratories) and Schering-Plough/Merck. A graduate of Rutgers University, Dr. Barat earned his Ph.D. in biomedical sciences, pharmacology and toxicology from the University of Medicine and Dentistry of New Jersey Medical School.
Positions
- Company NameHTG Molecular Diagnostics, Inc.Stock CodeHTGMQPositionSenior Vice President of TherapeuticsColleagues
- JLJohn L. LubniewskiPresident, CEO & Director
- AFAnn F. HanhamIndependent Chairman of the Board
- LLLaura Lee GodlewskiSenior Vice President of Finance & Administration
- DADebra A. GordonSenior VP & Chief Legal Counsel
- PCPatrick C. RocheSenior Vice President of Research & Development
- CPChristopher P. KiritsyNon-Employee Independent Director
- LRLee R. McCrackenIndependent Director
- MGMichelle GriffinIndependent Director
